Reducing Hypoglycemic, Pro-coagulant and Pro-atherothrombotic Responses and Preventing Hypoglycemia Associated Autonomic Failure in Type 1 DM. the Effects of Glucagon-like Peptide-1
Who is this study for? Patients with Type 1 Diabetes
What treatments are being studied? Glucagon-Like Peptide-1
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
The hypotheses to be tested in this application is: GLP-1 will acutely protect arterial endothelial function and reduce pro-atherothrombotic and pro-coagulant effects of repeated hypoglycemia in T1DM.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: f
View:
• 40 (20 males, 20 females) individuals with type 1 diabetes aged 18-50 yr.
• HbA1c \< 11.0%
• Body mass index \< 40kg • m-2
• No clinically diagnosed diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc)
Locations
United States
Maryland
University of Maryland
RECRUITING
Baltimore
Contact Information
Primary
Maka Siamashvili, MD
msiamashvili@som.umaryland.edu
410-706-5623
Backup
Stephen N Davis, MBBS
Time Frame
Start Date: 2020-06-24
Estimated Completion Date: 2026-09
Participants
Target number of participants: 40
Treatments
Placebo_comparator: Placebo 1
The participants will be randomized to placebo infusion.
Placebo_comparator: Placebo 2
The participants will be randomized to placebo infusion.
Experimental: GLP-1
The participants will be randomized to Glucagon-like peptide-1 infusion.
Related Therapeutic Areas
Sponsors
Leads: University of Maryland, Baltimore